前收市價 | 5.79 |
開市 | 4.62 |
買盤 | 4.50 |
賣出價 | 5.50 |
拍板 | 42.50 |
到期日 | 2024-07-19 |
今日波幅 | 4.62 - 5.79 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 1.15k |
The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.
Ionis Pharmaceuticals (IONS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.